▎药明康德

上海，2024年7月19日——药明康德今日宣布，公司连续第二年入选“富时罗素社会责任指数系列 ” （FTSE4Good Index Series），充分展现了药明康德在环境、社会及管治（ESG）方面的卓越表现。 药明康德始终致力于推进可持续发展战略，不断赋能创新，与行业同仁一起构建更健康美好的未来。

富时罗素社会责任指数系列由全球指数和数据提供商富时罗素（FTSE Russell）设立，旨在衡量企业在ESG实践领域 的突出表现。 富时罗素基于企业在公司治理、健康与安全、反腐败和气候变化等方面的表现进行独立评估，只有符合各项环境、社会和治理标准的企业才会被纳入社会责任指数系列。 在此次评估中，药明康德的得分高于全球行业标准。

“我们很高兴再次凭借卓越的ESG表现入选富时罗素社会责任指数系列，”药明康德副董事长兼ESG委员会主席胡正国先生表示，“药明康德始终坚定不移地推进ESG战略和可持续发展理念，积极履行我们对全球客户及各界的承诺。通过独特的CRDMO和CTDMO模式，药明康德将持续赋能客户，推动创新疗法早日上市，造福全球患者，共同创造更健康、更可持续的未来。”

作为创新的赋能者、客户信赖的合作伙伴以及全球健康产业的贡献者，药明康德将ESG理念融入公司战略和运营的方方面面。2024年，公司加入了“联合国全球契约组织”（United Nations Global Compact，UNGC），承诺支持全球契约十项原则；2023年，公司加入“科学碳目标倡议”（Science Based Targets initiative，SBTi）以减少碳排放；2023和2024年，公司连续2年入选标普全球可持续发展年鉴，并同时获评Sustainalytics“行业最高评级”和“区域最高评级”企业。药明康德出色的ESG表现也受到了MSCI、CDP和EcoVadis等全球ESG评级机构的高度认可。

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、精准医疗研发、测试和生产等领域。2023年，药明康德连续第三年被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的6000多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。

WuXi AppTec Named to the FTSE4Good Index Series for the Second Consecutive Year

Shanghai, July 19, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced that it has been included in the FTSE4Good Index Series for the second consecutive year. This achievement recognizes WuXi AppTec's exceptional performance in environmental, social, and governance (ESG) practices driven by our commitment to advancing sustainability and enabling innovation for a healthier world.

Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong ESG practices. FTSE Russell evaluations are based on performance in areas such as Corporate Governance, Health & Safety, Anti-Corruption and Climate Change.  Businesses included in the FTSE4Good Index Series meet a variety of environmental, social and governance criteria. FTSE Russell’s independent assessment scored WuXi AppTec above global industry standards.

“We are delighted to be recognized by the FTSE4Good Index Series for our exceptional ESG performance,” said Edward Hu, Vice Chairman of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee. “WuXi AppTec remains steadfast in its commitment to prioritize ESG initiatives and sustainable operations while delivering for our customers worldwide. Through our unique CRDMO and CTDMO business models, we continue to support customers’ needs by developing and delivering innovative new therapies to patients worldwide, working together towards a healthier and more sustainable future.”

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates ESG priorities in all aspects of its business operations. In 2024, WuXi AppTec joined the United Nations Global Compact (UNGC) in support of its ten sustainability principles and joined the Science Based Targets initiative (SBTi) to reduce carbon emissions in 2023 . In 2023 and 2024, WuXi AppTec was named to the S&P Global Sustainability Yearbook and recognized as an Industry and Regional “Top-Rated” company by Sustainalytics. WuXi AppTec’s outstanding ESG performance has been widely acknowledged by major global ESG rating agencies, including MSCI, CDP, and EcoVadis.

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."